Stifel Financial Corp Has $25.43 Million Stock Position in Sanofi (NASDAQ:SNY)

Stifel Financial Corp trimmed its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 527,170 shares of the company's stock after selling 35,377 shares during the quarter. Stifel Financial Corp's holdings in Sanofi were worth $25,425,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Tower Research Capital LLC TRC grew its position in Sanofi by 33.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,174 shares of the company's stock worth $153,000 after acquiring an additional 792 shares during the last quarter. Teachers Retirement System of The State of Kentucky boosted its stake in Sanofi by 7.2% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 409,290 shares of the company's stock worth $19,740,000 after purchasing an additional 27,330 shares in the last quarter. MML Investors Services LLC grew its holdings in shares of Sanofi by 4.7% during the fourth quarter. MML Investors Services LLC now owns 241,401 shares of the company's stock worth $11,643,000 after purchasing an additional 10,865 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Sanofi by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 164,538 shares of the company's stock valued at $7,936,000 after buying an additional 5,198 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Sanofi by 5.2% in the fourth quarter. First Trust Advisors LP now owns 895,324 shares of the company's stock valued at $43,181,000 after buying an additional 44,027 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Trading Down 2.3 %

NASDAQ SNY traded down $1.22 during trading hours on Friday, hitting $52.32. The company's stock had a trading volume of 5,488,689 shares, compared to its average volume of 2,365,342. The stock has a fifty day moving average of $54.53 and a 200 day moving average of $52.05. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The firm has a market capitalization of $132.17 billion, a P/E ratio of 21.01, a PEG ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a $2.0369 dividend. This represents a dividend yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. BNP Paribas began coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.